Aqua Pharmaceuticals Welcomes Kimberley Forbes-Mckean as Vice President of Research and Development

“Kimberley’s background in the biotech and pharmaceutical industry, with extensive experience in dermatological product development, will be a strong addition to the Aqua team,” said Jay Gooding, Aqua CEO. “Her unique perspective on our business strategy and objectives will no doubt lead to her contributing significantly to Aqua’s future success.” Dr. Forbes-McKean brings over 20 years of experience in pharmaceutical development, and over 15 of those years have been in the area of dermatological drug and device development. Most recently, she was Executive Vice President and Chief Scientific Officer at Cutanea Life Sciences, Inc. since it was founded in 2005. Prior to Cutanea,

Dr. Forbes-McKean was Senior Vice President and Chief Technical Officer at Isolagen, Inc.; Vice President of Global Dermatological Product Development and Commercialization at Aventis Pharmaceutical, Inc.; and Worldwide Director of Dermatological Product Development at Dermik, Inc (a division of Aventis). In her role at Aventis/Dermik, she was primarily responsible for product development, project management, business development, regulatory and quality strategy, and her team was responsible for multiple product approvals leading to international commercialization of at least one new product each year. While there, she also created an independent project management department to focus on the development of dermatological products and portfolio management to provide strategic scientific direction and prioritize activities to meet the profit targets of the business unit.

Dr. Forbes-McKean holds a Ph.D. and an M.S. in analytical chemistry from the University of Massachusetts at Amherst, Mass., and a B.S. in chemistry from Union College in Schenectady, N.Y.